4-[4-[2-(4-hydroxy-3,5-ditert-butyl-phenyl)sulfanylpropan-2-ylsulfanyl]-2,6-ditert-butyl-phenoxy]-4-oxo-butanoic acid
4-[4-[2-(4-hydroxy-3,5-ditert-butyl-phenyl)sulfanylpropan-2-ylsulfanyl]-2,6-ditert-butyl-phenoxy]-4-oxo-butanoic acid Basic information
- Product Name:
- 4-[4-[2-(4-hydroxy-3,5-ditert-butyl-phenyl)sulfanylpropan-2-ylsulfanyl]-2,6-ditert-butyl-phenoxy]-4-oxo-butanoic acid
- Synonyms:
-
- SUCCINOBUCOL
- AGI-1067;PROBUCOL MONOSUCCINATE
- Probucol monosuccinate, >98%
- SUCCINOBUCOL, >98%
- AGZ-1067
- AGZ1067. Probucol monosuccinae
- SUCCINOBUCOL; AGI-1067; AGZ-1067; AGI1067; AGZ1067. PROBUCOL MONOSUCCINAE
- Succinobucol(AGI 1067)
- CAS:
- 216167-82-7
- MF:
- C35H52O5S2
- MW:
- 616.91
- Product Categories:
-
- Aromatics
- Intermediates & Fine Chemicals
- Pharmaceuticals
- Sulfur & Selenium Compounds
- Mol File:
- 216167-82-7.mol
4-[4-[2-(4-hydroxy-3,5-ditert-butyl-phenyl)sulfanylpropan-2-ylsulfanyl]-2,6-ditert-butyl-phenoxy]-4-oxo-butanoic acid Chemical Properties
- Melting point:
- 139 - 142°C
- Boiling point:
- 659.5±55.0 °C(Predicted)
- Density
- 1.13±0.1 g/cm3(Predicted)
- storage temp.
- 2-8°C
- solubility
- Chloroform (Slightly), Methanol (Slightly)
- pka
- 4.27±0.17(Predicted)
- form
- Solid
- color
- White to Light Yellow
4-[4-[2-(4-hydroxy-3,5-ditert-butyl-phenyl)sulfanylpropan-2-ylsulfanyl]-2,6-ditert-butyl-phenoxy]-4-oxo-butanoic acid Usage And Synthesis
Uses
An antioxidant and anti-inflammatory.
Definition
ChEBI: Succinobucol is a benzoate ester and a member of phenols.
Biological Activity
Succinobucol is a metabolically stable derivative of the antioxidant drug probucol th at poses a distinct pharmacological from. Succinobucol is an orally active vascular protectant th at exhibits antiatherosclerotic properties in multiple animal models and in humans. It inhibits the release of proinflammatory cytokines, TNF-a, IL-1b, and IL-6 in hPBMC activated by LPS.
in vivo
Succinobucol (50, 100, and 150 mg/kg, i.v.) has no significant effect on either heart rate or MAP, but the blood removed 15 minutes after the final injection of succinobucol shows significantly less aggregation in response to collagen at both 5 μg/mL and 20 μg/mL in rats[1]. Succinobucol (40 mg/kg) by tail injection significantly reduces the average number of metastatic nodules in lung metastatic breast cancer mice[3].
4-[4-[2-(4-hydroxy-3,5-ditert-butyl-phenyl)sulfanylpropan-2-ylsulfanyl]-2,6-ditert-butyl-phenoxy]-4-oxo-butanoic acidSupplier
- Tel
- 18210857532; 18210857532
- jkinfo@jkchemical.com
- Tel
- 1-(800)-881-8210
- inquiries@lgmpharma.com
- Tel
- 021-50135380
- shchemsky@sina.com
- Tel
- 021-58955995
- sales@medchemexpress.cn
- Tel
- 13621943973
- sales@shjiyipharmatech.com